Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Net Asset Momentum
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) recorded a net asset momentum of -53.2% as of December 2025, with net assets of $-176.63 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. For live market cap and overall valuation, see Hemab Therapeutics Holdings, Inc. Common stock valuation.
YoY Momentum
Current Net Assets
Years of Data
Country
Hemab Therapeutics Holdings, Inc. Common Stock Net Asset Momentum (2024–2025)
This chart tracks Hemab Therapeutics Holdings, Inc. Common Stock's year-over-year net asset growth across 2 annual reporting periods from 2024 to 2025. The most recent momentum reading is -53.2%, with net assets of $-176.63 Million USD as of December 2025. See debt-free asset ratio of Hemab Therapeutics Holdings, Inc. Common to measure how much of total assets are equity-financed.
Annual Net Asset History for Hemab Therapeutics Holdings, Inc. Common Stock (2024–2025)
The table below shows the complete annual net asset history for Hemab Therapeutics Holdings, Inc. Common Stock from 2024 to 2025, covering 2 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. See financial agility of Hemab Therapeutics Holdings, Inc. Common to measure the company's free cash flow as a share of total liabilities.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $-176.63 Million | $194.78 Million | $371.42 Million | ▼ -53.2% |
| 2024 | $-115.27 Million | $96.28 Million | $211.55 Million | — |